trending Market Intelligence /marketintelligence/en/news-insights/trending/tjjlhetd66qrs8ppwyujqg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Calithera BioSciences Inc. is partnering with Bristol-Myers Squibb Co. to determine whether its CB-839 drug can be combined with Opdivo to treat kidney cancer.

Bristol-Myers' Opdivo is already approved as a treatment for certain types of cancer. CB-839 is currently in phase 1/2 clinical studies involving patients with clear cell renal cell carcinoma.